Effects of early retinoic acid signaling on valve development

Active Project Grant Awarded Last action

Award ID
F31HL172346
Recipient
Awarding agency
Obligated
$335,592

Award facts

Assistance listing
93.837 Cardiovascular Diseases Research
Completion date 64% complete
Place of performance
Cincinnati, OH 45229, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Congenital valve defects (cvds) constitute some of the most common human congenital heart defects (chds). Cvds that lead to valve disease later in life, which can result in heart failure, stroke, blood clots, and even sudden cardiac arrest. The most common therapy for valve diseases is invasive valve replacement surgery, which is one of the most common procedures in the cardiac surgery market at nearly 182,000 per year in the USA, making up nearly a quarter of the total procedural volume. Therefore, elucidating the early developmental and patterning mechanisms driving normal cardiac valve development will give US novel insight into the etiology of cvds. Retinoic acid (RA) is the most active metabolic product of vitamin a (retinol) within vertebrate embryos and is reiteratively required for normal vertebrate heart development. Perturbations of RA signaling have been associated with multiple types of chds, including cvds, as well as valve diseases at later stages of development. However, embryos devoid of early RA exhibit enlarged hearts due to the increased specification and differentiation of cardiomyocytes. Despite the known requirements in heart development and previous studies implying RA signaling is required for cardiac valve formation and maintenance, we still do not have clear understanding of the requirements of early RA signaling in vertebrate valve development. Our preliminary work using zebrafish shows that early inhibition of RA signaling results in an enlarged atrioventricular canal (AVC), characterized by an expansion of myocardial AVC markers, which is consistent with the enlarged hearts in RA deficient embryos. Surprisingly, despite the enlargement of the myocardial AVC region in RA deficient embryos and expectation that this would result in typically larger valves, we find that the overlying atrioventricular valves (avvs) do not form, suggesting that a factor signaling from the myocardium to the overlying endocardium necessary to promote AVV induction is lost. Our preliminary data show that canonical WNT signaling is lost within AVC cardiomyocytes following early inhibition of RA, suggesting that we have identified a new signaling node necessary to promote normal AVV development. In aim 1, we will test the hypothesis that early RA signaling directly establishes cardiac progenitors sufficient to turn on WNT signaling later in the AVC myocardium required for AVV development. In aim 2, we will test the hypothesis that WNT signaling functions downstream of early RA signaling in the induction of avvs. Ultimately, the proposed studies could be used to identify and develop new therapeutic approaches for treatment to prevent or ameliorate cvds and their resulting valve diseases.

Transactions

Action Obligated Date
Amendment $576
Amendment $42,479
Amendment $42,479
Amendment $564
Amendment $564
Amendment $41,915
Amendment $41,915
Amendment $1,280
Amendment $1,280
Amendment $40,635
Amendment $0
Amendment $40,635
Amendment $40,635
Amendment $0
Amendment $40,635
Original award $0
Show all 16

Quick answers

Who received award F31HL172346?

F31HL172346 was awarded to Childrens Hospital Medical Center by National Heart Lung and Blood Institute (National Institutes of Health) on July 20, 2024.

How much is award F31HL172346 worth?

$335,592 has been obligated on F31HL172346.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login